William Fischer, MD, associate professor of medicine in the division of pulmonary and critical care medicine, who led UNC trials to determine if Molnupiravir could be a possible treatment for COVID-19, was quoted in a CBS-17 News report about its potential to change the way COVID-19 is treated.
“The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals treated with Molnupiravir, are promising and if supported by additional studies could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally,” said Fischer in a news release distributed by the dug maker.
Cameron Wolfe, MD, who led the Molnupiravir study at Duke, compared the pill to Tamiflu for influenza, as “a broad acting antiviral agent.”
Read the news story here.